- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07660549
TheraCal Materials Versus MTA in Full Pulpotomy
Can TheraCal LC and TheraCal PT Match MTA in Full Pulpotomy? A Twelve-Month Randomized Clinical Trial in Permanent Molars With Symptomatic Irreversible Pulpitis
The goal of this randomized clinical trial is to compare the clinical performance of three pulp capping materials used in full pulpotomy procedures in mature mandibular molars with symptomatic irreversible pulpitis.
The main questions it aims to answer are:
- Does full pulpotomy using mineral trioxide aggregate (MTA) provide favorable postoperative pain control and 12-month clinical success?
- Does full pulpotomy using TheraCal LC provide comparable postoperative pain control and 12-month clinical success to MTA?
- Does full pulpotomy using TheraCal PT provide comparable postoperative pain control and 12-month clinical success to MTA?
Participants will undergo full pulpotomy treatment in mandibular first or second molars diagnosed with symptomatic irreversible pulpitis. After removal of the coronal pulp tissue and achievement of hemostasis, teeth will be randomly assigned to one of three treatment groups.
In the MTA group, the exposed radicular pulp tissue will be covered with mineral trioxide aggregate.
In the TheraCal LC group, the exposed radicular pulp tissue will be covered with light-cured resin-modified calcium silicate material.
In the TheraCal PT group, the exposed radicular pulp tissue will be covered with dual-cured resin-modified calcium silicate material.
Postoperative pain intensity, analgesic intake, and 12-month clinical outcomes will be compared among the three groups.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Действительный)
Фаза
- Непригодный
Контакты и местонахождение
Места учебы
-
-
Sarıçam
-
Adana, Sarıçam, Турция (Туркие), 01250
- Cukurova University
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
- Взрослый
- Пожилой взрослый
Принимает здоровых добровольцев
Описание
Inclusion Criteria:
- Patients requiring full pulpotomy treatment in mandibular first or second permanent molars diagnosed with symptomatic irreversible pulpitis.
- Mandibular first or second permanent molars with a preoperative Visual Analogue Scale (VAS) pain score ≥4, indicating moderate or severe pain.
- Vital mandibular first or second permanent molars showing positive responses to both cold and electric pulp tests.
- Teeth with deep carious lesions indicated for vital pulp therapy.
- Teeth with no radiographic evidence of periapical pathology.
- Patients who had not taken analgesics or antibiotics within the 24 hours preceding the procedure.
Exclusion Criteria:
- Non-vital mandibular permanent molars showing negative responses to cold or electric pulp tests.
- Non-restorable teeth.
- Teeth with root caries, open apex, pulp calcification, internal or external resorption, or periodontal involvement.
- Mandibular first or second permanent molars with poor periodontal status, defined as periodontal pocket depth >4 mm.
- Teeth with radiographic evidence of periapical pathology.
- Patients with systemic conditions such as uncontrolled hypertension, uncontrolled diabetes mellitus, chronic kidney disease, hematological disorders, or a history of chemotherapy or radiotherapy.
- Patients with contraindications to full pulpotomy treatment or local anesthesia.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Фундаментальная наука
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Одинокий
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Активный компаратор: MTA Group
After removal of the coronal pulp tissue and achievement of hemostasis, the exposed radicular pulp tissue was covered with mineral trioxide aggregate (MTA).
The material was placed over the pulp surface at a thickness of approximately 2-4 mm and gently condensed.
A moist sterile cotton pellet was then placed over the material for approximately 10 minutes to allow initial setting.
The tooth was subsequently restored using a standardized restorative protocol.
|
In the MTA group, after full pulpotomy and achievement of hemostasis, the exposed radicular pulp tissue was covered with mineral trioxide aggregate.
The material was placed over the pulp surface at a thickness of approximately 2-4 mm and gently condensed.
|
|
Экспериментальный: TheraCal LC Group
After removal of the coronal pulp tissue and achievement of hemostasis, the exposed radicular pulp tissue was covered with TheraCal LC, a light-cured resin-modified calcium silicate material.
The material was applied in increments not exceeding 1 mm to ensure adequate polymerization.
Each increment was light-cured for 20 seconds, and the total material thickness was approximately 2-3 mm.
The tooth was subsequently restored using a standardized restorative protocol.
|
In the TheraCal LC group, after full pulpotomy and achievement of hemostasis, the exposed radicular pulp tissue was covered with TheraCal LC, a light-cured resin-modified calcium silicate material.
The material was applied in increments not exceeding 1 mm, and each increment was light-cured for 20 seconds.
|
|
Экспериментальный: TheraCal PT Group
After removal of the coronal pulp tissue and achievement of hemostasis, the exposed radicular pulp tissue was covered with TheraCal PT, a dual-cured resin-modified calcium silicate material.
The material was applied as a single layer at a thickness of approximately 2-3 mm and light-cured for 20 seconds using an LED curing unit.
The tooth was subsequently restored using a standardized restorative protocol.
|
In the TheraCal PT group, after full pulpotomy and achievement of hemostasis, the exposed radicular pulp tissue was covered with TheraCal PT, a dual-cured resin-modified calcium silicate material.
The material was applied as a single layer at a thickness of approximately 2-3 mm and light-cured for 20 seconds.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Postoperative Pain Intensity Assessed by Visual Analogue Scale
Временное ограничение: Preoperative baseline, 24 hours, 72 hours, 7 days, and 14 days after treatment
|
Postoperative pain intensity will be assessed using a Visual Analogue Scale (VAS) ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable.
Participants will record their pain intensity at predetermined postoperative time points after full pulpotomy treatment.
VAS scores will be compared among the MTA, TheraCal LC, and TheraCal PT groups.
|
Preoperative baseline, 24 hours, 72 hours, 7 days, and 14 days after treatment
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Koray Yılmaz, DDS, MSc, Professor, Cukurova University
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- 06.12.2024/16
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .